Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 06, 2024 11:33am

108 Views

Post# 35918168

RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

March 04, 2024 - Pfizer stops buildout of Seagen $350 Million plant.

Clinical production of Seagen’s pipeline drugs will take place at other sites in Pfizer’s network, it said.

https://www.fiercepharma.com/pharma/pfizer-sacks-seagen-manufacturing-site-impacting-120-staffers

<< Previous

Bullboard Posts

Next >>

B2Gold stock buckles under news of labour strike in Mali